CELULARITY INC-A (CELU)

US1511902041 - Common Stock

3  -0.05 (-1.64%)

Fundamental Rating

1

CELU gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. CELU may be in some trouble as it scores bad on both profitability and health. CELU is valued expensive and it does not seem to be growing.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CELU has reported negative net income.
CELU had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CELU reported negative net income in multiple years.
CELU had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -115.41%, CELU is not doing good in the industry: 82.22% of the companies in the same industry are doing better.
CELU has a Return On Equity of -599.78%. This is amonst the worse of the industry: CELU underperforms 81.03% of its industry peers.
CELU has a Return On Invested Capital of 26.17%. This is amongst the best in the industry. CELU outperforms 99.66% of its industry peers.
Industry RankSector Rank
ROA -115.41%
ROE -599.78%
ROIC 26.17%
ROA(3y)-7.18%
ROA(5y)-4.14%
ROE(3y)-31.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CELU has a Operating Margin of 240.86%. This is amongst the best in the industry. CELU outperforms 100.00% of its industry peers.
CELU has a Gross Margin of 21.18%. This is in the better half of the industry: CELU outperforms 75.21% of its industry peers.
Industry RankSector Rank
OM 240.86%
PM (TTM) N/A
GM 21.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

CELU has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CELU has been increased compared to 1 year ago.
Compared to 1 year ago, CELU has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -6.95, we must say that CELU is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.95, CELU is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.16 is on the high side and indicates that CELU has dependencies on debt financing.
CELU has a worse Debt to Equity ratio (1.16) than 78.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Altman-Z -6.95
ROIC/WACC3.6
WACC7.27%

2.3 Liquidity

CELU has a Current Ratio of 0.19. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.19, CELU is doing worse than 98.63% of the companies in the same industry.
CELU has a Quick Ratio of 0.19. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CELU (0.14) is worse than 98.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.14

More info and screens

2

3. Growth

3.1 Past

CELU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -7175.00%.
Measured over the past years, CELU shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -33.78% on average per year.
Looking at the last year, CELU shows a very negative growth in Revenue. The Revenue has decreased by -20.96% in the last year.
EPS 1Y (TTM)-7175%
EPS 3Y-33.78%
EPS 5YN/A
EPS growth Q2Q-16766.67%
Revenue 1Y (TTM)-20.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-8.55%

3.2 Future

The Earnings Per Share is expected to decrease by -153.45% on average over the next years. This is quite bad
CELU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.83% yearly.
EPS Next Y-1290%
EPS Next 2Y-362.39%
EPS Next 3Y-153.45%
EPS Next 5YN/A
Revenue Next Year219.12%
Revenue Next 2Y-0.02%
Revenue Next 3Y49.44%
Revenue Next 5Y70.83%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CELU is valued cheaply inside the industry as 98.80% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.47

4.3 Compensation for Growth

A cheap valuation may be justified as CELU's earnings are expected to decrease with -153.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-362.39%
EPS Next 3Y-153.45%

More info and screens

0

5. Dividend

5.1 Amount

CELU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (5/17/2024, 7:00:00 PM)

3

-0.05 (-1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap65.34M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.41%
ROE -599.78%
ROCE
ROIC
ROICexc
ROICexgc
OM 240.86%
PM (TTM) N/A
GM 21.18%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.19
Quick Ratio 0.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-7175%
EPS 3Y-33.78%
EPS 5Y
EPS growth Q2Q
EPS Next Y-1290%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.96%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y